Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the safety of intravitreal aflibercept
injection in treating visually compromising radiation maculopathy secondary to treatment of
uveal melanoma by iodione-125 brachytherapy. The study will consist of two arms of 25
patients each (totaling 50 patients). Subjects in arm 1 will undergo treatment every 6 weeks.
Subjects in arm 2 will undergo treatment and if improvement is documented at the following
evaluation the next treatment will be extended by two weeks. Secondary objectives of the
study include evaluation and analysis of visual acuity, number of injections, macular edema,
and vascular activity between both arms.